上海罗氏制药昨天在沪宣布说，继成功用于HER2阳性乳腺癌治疗之后，抗HER2靶向药物赫赛汀(曲妥珠单抗)在胃癌治疗领域同样实现重大突破。赫赛汀联合化疗已正式被国家食药监局批准用于HER2阳性转移性胃癌的一线治疗。

Shanghai roche pharmaceuticals announced yesterday in Shanghai said,After successfully used in positive HER2 breast cancer after treatment,Anti HER2 targeted drugs Hector and Hastings(Song completed bead sheet resistance)In the field of treatment of gastric cancer also achieve significant breakthrough.Hector "kristin combination chemotherapy has officially by the national food administration for HER2 positive metastatic gastric cancer of the first line therapy.

　　“这意味着我国胃癌治疗进入了分子靶向时代，让人们看到了晚期胃癌个体化治疗的希望。”中国抗癌协会临床肿瘤学协作专业委员会主任委员秦叔逵教授在接受采访时表示，胃癌是我国高发的消化道恶性肿瘤，总体预后不佳。赫赛汀联合化疗在HER2阳性晚期胃癌患者中的疗效显著优于单纯化疗，预示着一部分晚期胃癌患者的预后有望得到改善。

"This means that our country gastric cancer treatment into the molecular targeted era,Let people see the hope of advanced gastric cancer individualization treatment."China anti-cancer association clinical oncology cooperation professional committee of the chairman of the committee QinShuKui professor said in an interview,Gastric cancer is the high incidence of digestive tract malignant tumor,Overall prognosis is not good.Hector "kristin combination chemotherapy in advanced gastric cancer patients in positive HER2 curative effect is significantly better than the pure chemotherapy,Indicates the part of the prognosis of patients with advanced gastric cancer is expected to be improved.

　　最新研究显示，胃癌与乳腺癌一样，按其人表皮生长因子受体-2(HER2)的状态，也可分为阴性或阳性。HER2阳性的患者病情易复发和转移。在胃癌患者中，约每6人中有1人为HER2阳性患者。一项名为ToGA的III期国际临床研究，在全球24个国家122个研究机构进行了胃癌对照试验，证实HER2阳性晚期、无法手术的胃癌患者，接受赫赛汀联合化疗能降低35%的死亡风险、显著延长总生存期，还能改善转移性胃癌患者的生存质量。

The latest research shows that,Gastric cancer and breast cancer as,According to the person epidermal growth factor receptor - 2(HER2)state,Also can be divided into negative or positive.HER2 positive patient easy relapse and metastasis.In gastric cancer patients,About every six people have 1 people with positive HER2.A ToGA called the phase III international clinical research,In 24 countries across 122 research institutions for the stomach cancer control test,Confirmed positive HER2 late/Can't surgery in patients with gastric cancer,Accept the hittite statins and combined chemotherapy can reduce the risk of death by 35%/Significantly extend the total life cycle,Can also improve the metastatic gastric cancer patients quality of life.

　　秦叔逵教授强调说，胃癌患者在治疗前必然明确HER2状态，以获得更具针对性的个体化治疗方案。但目前我国胃癌患者对HER2检测的认知度普遍较低，HER2检测度不足10%，导致一些阳性胃癌患者错失治疗良机。

QinShuKui professor emphasizes said,In patients with gastric cancer before treatment must clear HER2 state,To get more specific individualization treatment.But at present our country gastric cancer patients to HER2 detection awareness is generally low,HER2 detection of less than 10%,Cause some positive patients with gastric cancer treatment opportunity missed.

　　我国每年新发胃癌病例约40万。由于早期隐匿性强，临床确诊的胃癌病人以三期和四期居多，很难通过手术完全根治。胃癌患者的5年生存率为5%-20%，总体平均生存时间小于1年。(记者 施捷）

Every year in our country new cases of gastric cancer cases about 400000.Due to the strong early stealthiness,Clinically diagnosed gastric cancer patients with three phase and four period is in the majority,It is difficult to surgically radical.Gastric cancer patients with 5 years survival rate is 5% - 20%,The overall average survival time less than 1 year.(Reporter ShiJie)